Position in PFE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,489,558
+$1,683,045 QoQ
Shares Held
103,387
+260.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#866
of 2,821 holders
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SummitTX Capital, L.P. holds $15,756,921 across 8 Drug Manufacturers - General names. PFE ranks #4 (15.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
41,589 | $5,254,354 | |
| 2 | LLY |
ELI LILLY & Co
|
2,362 | $2,833,053 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
44,239 | $2,549,051 | |
| 4 | PFE |
Pfizer Inc
This page
|
103,387 | $2,489,558 | |
| 5 | ABBV |
AbbVie Inc.
|
3,743 | $941,888 | |
| 6 | JNJ |
Johnson & Johnson
|
3,540 | $899,053 | |
| 7 | BIIB |
Biogen Inc.
|
1,872 | $404,464 | |
| 8 | MRK |
Merck & Co., Inc.
|
3,000 | $385,500 |
All Filings in PFE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,489,558 | 103,387 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $806,513 | 28,722 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $1,823,858 | 71,580 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $10,623,858 | 438,278 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $4,075,533 | 160,834 | Shares | Defined | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||